Five year outcome of lentiviral gene therapy for human beta-thalassemia, lessons and prospects

Philippe Leboulch

*Institute of Emerging Diseases and Innovative Therapies, INSERM U. 962, University Paris 11
Bluebird bio, France and Harvard Medical School, Brigham and Women's Hospital, Boston, MA*

Oral presentation

Oral presentation is available online

Correspondence: Philippe Leboulch

©Copyright P. Leboulch, 2013
Licensee PAGEPress, Italy
Thalassemia Reports 2013; 3(s1):e43
doi:10.4081/thal.2013.s1.e43

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 3.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

*Parts of this work were presented at the
"3rd Pan-European Conference on Haemoglobinopathies and Rare Anaemias",
Limassol (Cyprus), 24-26 October 2012.*